Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Coal mining's occupational danger affects black lung disease therapy. Long-term coal dust exposure is connected to black lung disease, often known as coal workers' pneumoconiosis. Despite mining safety improvements, this occupational risk drives need for effective therapies.
Black lung disease is rising, especially in coal mining areas. This increase in incidence is due to poor dust management, inadequate protective equipment, and exposure to finer coal dust particles, demanding a fresh emphasis on prevention and treatment.
Diagnostic tools for black lung disease are improving. HRCT scans and other imaging modalities help healthcare practitioners discover the condition early and accurately, allowing them to intervene and control it.
The black lung disease market emphasizes prevention. Black lung disease may be reduced and its effects mitigated by strict workplace safety enforcement, dust control, and coal miner respiratory gear.
Rehabilitation and support are crucial to black lung disease management. Pulmonary rehabilitation helps enhance lung function, along with symptoms, and also overall well-being. To treat illness symptoms and consequences, oxygen treatment and medicines are used.
Black lung disease worker rights advocacy is growing. Awareness of the disease's effect on coal miners has led to requests for better working conditions, healthcare, compensation, and assistance for afflicted persons and their families.
Black lung disease treatment is increasingly using telemedicine for consultations and follow-up. This method is useful for remote miners who have trouble getting specialist treatment.
Government laws and regulations shape the black lung disease market. To reduce black lung disease, strict coal dust laws, mining safety requirements, and proper healthcare and compensation for afflicted workers are needed.
Global collaborations are helping to study and treat black lung disease. Healthcare institutions, government agencies, and advocacy organizations are working together to uncover risk factors, enhance diagnostic methods, and create new occupational lung disease therapies.
Support services for black lung disease patients are developing due to their mental effect. Coal miners with black lung disease suffer emotional and social issues that counseling, mental health assistance, and community initiatives address.
Market trends are affected by environmental and occupational health measures. Cleaner energy, coal reduction, and sustainable mining are being promoted as ways to reduce black lung disease and safeguard workers.
Black Lung Disease Market Highlights:
Global Black Lung Disease Market Overview
Black Lung Disease Market Size was valued at USD 12.43 Billion in 2023. The Global Black Lung Disease industry is projected to grow from USD 13.21 Billion in 2024 to USD 20.73 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.36% during the forecast period (2024 - 2032).
Black lung disease or coal workers' pneumoconiosis is caused by long exposure to coal dust and is commonly diagnosed in many of the coal miners. The medical condition is characterized by a progressive building of the inhaled coal dust in the lungs, which may lead to inflammation, fibrosis, necrosis, and others. Increasing prevalence of black lung disease is one of the major drivers of market growth during the forecast period. According to the 2005-2016 report of the Health and Safety Executive, it was estimated that the average number of new cases for black lung disease was 25 (on a yearly basis). Moreover, increasing mining activities, increasing research and development expenses, and rising healthcare expenditures boost the market growth. In 2015, according to the Office for National Statistics, the total healthcare expenditure was estimated to about USD 271 billion within U.K.
However, factors such as lack of awareness, limited availability of medicinal treatment options followed by the high cost of surgical therapeutics including lung transplantation and stem cell therapy are estimated to restrain the market growth during the forecast period. In 2016, the average cost of lung transplantation was expected to be around USD 111, 618.
Global Black Lung Disease Market Segmentation
The global black lung disease market is segmented by the type, diagnosis, treatment, and end-user.
On the basis of the type, the black lung disease market is segmented into simple coal worker’s pneumoconiosis, complicated coal worker’s pneumoconiosis, and others.
On the basis of the diagnosis, the market is segmented into biopsy, imaging, full blood count, pulmonary/lung function tests, physical examination, and others. The imaging segment is segmented into CT, X-ray, and others.
On the basis of the treatment, the market is segmented into oxygen therapy, bronchodilators, lung transplant, stem cell therapy, and others.
On the basis of the end users, the market is segmented into hospitals & clinics, research organizations & academic institutes, diagnostic centers & labs, and others.
Global Black Lung Disease Market Regional Analysis
The Americas dominate the global black lung disease market owing to a well-developed healthcare sector and huge patient population. Moreover, increasing healthcare expenditure and presence of the key players like GENERAL ELECTRIC and Medtronic within the regions boosts the growth of the market in the Americas. Additionally, developed economies of the region like U.S. and Canada boost.
Europe is the second largest market for black lung disease and is followed by Asia Pacific. Rising government support, huge patient population, and rising healthcare expenditure are some of the major drivers for market growth within the region. On a regional basis, the European black lung disease market is segmented into Western Europe and Eastern Europe. Western Europe is estimated to lead the regional market due to the presence of developed economies like Germany, U.K, France, and others within the region.
Asia Pacific is the fastest growing region for the black lung disease market. Factors such as the presence of a huge patient population, continuously developing healthcare sector, and rising healthcare expenditure drives the market growth within the region. In 2017, a study published in the International Journal of Environmental Research and Public Health journal stated that the number of new cases for pneumoconiosis was about 26,873 in 2014, of which about 13,846 (51.52%) accounted for black lung disease.
The Middle East & Africa has the least share in the global black lung disease market. Presence of poor economies, lack of a developed healthcare sector, stringent government policies, and lack of awareness of the disease, restrain the market growth, especially within the Africa region. A majority of the market of this region is held by the Middle East.
Key Players in Black Lung Disease Market
The key players for the global black lung disease market are:
- Boehringer Ingelheim International GmbH (Germany)
- GlaxoSmithKline plc (U.K)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- AstraZeneca (U.K)
- Koninklijke Philips N.V. (The Netherlands)
- GENERAL ELECTRIC (U.S.)
- Siemens AG (Germany)
- TOSHIBA CORPORATION (Japan)
- Medtronic (U.S.)
Intended Audience
- Pharmaceutical Companies
- Biotechnological Institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Research Methodology 
Sources: WHO, Health and Safety Executive, Office for National Statistics, Centers for Disease Control and Prevention, Annual Reports, Press Release, White Paper, And Company Presentation
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
